Novonesis takes full ownership of MicroBioGen for Novonesis stock

Published on 10/18/2026 at 12:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novonesis completed MicroBioGen on October 1, 2026 after holding 23 percent. West Allis capacity rose 66 percent for Novonesis stock.

Yeast strategy and capacity expansion

Novonesis secured full ownership of MicroBioGen on October 16, 2026, after a 23 percent stake.
West Allis fermentation capacity increased 66 percent under the September 28, 2026 expansion.
Novonesis stock closed at EUR 60.29 on October 16, 2026.

Aquarell einer daenischen Kuestenstadt mit modernen Buerogebaeuden am Wasser — Aquarellmalerei des Kopenhagener Hauptsitzes von Novonesis (Novozymes), ISIN DK0060336014, zeigt daenische Kuestenlandschaft mit weichen Wasserfarben, Illustration mit AI erstellt.

Novonesis takes full ownership of MicroBioGen as Novonesis stock enters a new phase for its yeast strategy. Piper Alderman said on October 16, 2026 that the sale had brought the Australian biotechnology company under Novonesis' full ownership. The transaction builds on Novonesis' investment in MicroBioGen in 2013.

Yeast deal adds a decade of ties

The acquisition was completed on October 1, 2026, after regulatory approvals, according to Yahoo Finance. Novonesis had previously owned 23 percent of MicroBioGen, whose yeast expertise covers industrial applications and bioethanol. The strategic value is therefore capability-led rather than a simple capacity purchase.

For investors, the chronology matters. Novonesis first invested in 2013, agreed to acquire the remaining stake in August 2026, and completed the transaction on October 1, 2026. The October 16 update from Piper Alderman adds confirmation from the transaction advisers that ownership is now complete.

What does capacity mean for growth?

Novonesis also expanded its West Allis production facility in Wisconsin. The National Law Review reported on September 28, 2026 that fermentation capacity increased 66 percent and packaging capacity rose 17 percent. The site employs 360 people and supplies dairy cultures across North America.

Next date is November 5

The next scheduled earnings date is November 5, 2026, according to Simply Wall St. That report should give investors a clearer view of how the MicroBioGen transaction and the expanded production footprint fit into Novonesis' financial outlook.

Stock closes before the next report

Novonesis stock closed at EUR 60.29 on October 16, 2026. The same instrument had a DKK 336.80 to DKK 465.00 52-week range and a DKK 187.6 billion market capitalization in the October 16 market snapshot.

The further course of trading is shown by the continuously updated real-time quote of Novonesis stock.